logo

Nabriva Therapeutics (NBRV)



Trade NBRV now with
  Date
  Headline
11/1/2021 7:14:51 AM Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9/9/2021 7:32:34 AM Nabriva Therapeutics Agrees With Vizient To Offer XENLETA To Vizient’s Pharmacy Network Program
9/1/2021 7:15:50 AM Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/1/2021 7:12:56 AM Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/26/2021 8:05:59 AM Nabriva Therapeutics Appoints Daniel Dolan As CFO
8/9/2019 9:47:14 AM Wedbush Is Cutting Nabriva Therapeutics (NBRV) FY20 Estimate To -1.02 From -0.30
8/9/2019 9:47:01 AM Wedbush Is Lowering Nabriva Therapeutics (NBRV) Q4 20 Estimate To -0.19 From -0.01
8/9/2019 9:46:49 AM Wedbush Is Lowering Nabriva Therapeutics (NBRV) Q3 20 Estimate To -0.39 From -0.06
8/9/2019 9:46:37 AM Wedbush Is Lowering Nabriva Therapeutics (NBRV) Q2 20 Estimate To -0.20 From -0.10
8/9/2019 9:46:25 AM Wedbush Is Lowering Nabriva Therapeutics (NBRV) Q1 20 Estimate To -0.24 From -0.13
8/9/2019 9:45:40 AM Wedbush Is Raising Nabriva Therapeutics (NBRV) FY19 Estimate To -1.04 From -1.14
8/9/2019 9:43:59 AM Wedbush Is Increasing Nabriva Therapeutics (NBRV) Q4 19 Estimate To -0.24 From -0.27
8/9/2019 9:43:48 AM Wedbush Is Increasing Nabriva Therapeutics (NBRV) Q3 19 Estimate To -0.21 From -0.25
8/9/2019 9:42:54 AM Wedbush Reiterates Nabriva Therapeutics (NBRV) At Outperform With $5 Price Target
5/14/2019 6:47:48 AM Wedbush Is Raising Nabriva Therapeutics (NBRV) FY19 Rev. Estimate To 6.2 M From 3.8 M
5/14/2019 6:47:36 AM Wedbush Is Lowering Nabriva Therapeutics (NBRV) Q4 19 Rev. Estimate To 1.9 M From 2.0 M
5/14/2019 6:47:25 AM Wedbush Is Raising Nabriva Therapeutics (NBRV) Q3 19 Rev. Estimate To 1.8 M From 0.3 M
5/14/2019 6:47:13 AM Wedbush Is Cutting Nabriva Therapeutics (NBRV) Q2 19 Rev. Estimate To 0.9 M From 1.1 M
5/14/2019 6:46:52 AM Wedbush Is Raising Nabriva Therapeutics (NBRV) FY19 Estimate To -1.14 From -1.18